Diabetic Retinopathy

Carolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss new and upcoming clinical trials, investigational therapies, and diagnostic tools for the treatment of diabetic retinopathy and diabetic macular edema (DR/DME).

Diabetic retinal disease experts discuss different approaches that can reduce the treatment burden while maintaining good visual outcomes during diabetic retinopathy and diabetic macular edema (DR/DME) therapy.

The findings from a National Institutes of Health-supported clinical trial may help guide the management of diabetic eye disease.

Rishi Singh, MD, provides an overview of the stages of diabetic retinopathy and diabetic macular edema (DR/DME) and the retinal findings associated with each stage as well as factors to consider when selecting therapy.

Carolyn Majcher, OD, FAAO, discusses when to refer patients with diabetic retinopathy and diabetic macular edema (DR/DME) to a retina specialist.

Carolyn Majcher, OD, FAAO, describes challenges primary eye care providers can experience when diagnosing diabetic retinopathy and diabetic macular edema (DR/DME).

Diabetic retinal disease experts discuss the standard diagnostic imaging tools that are available to detect diabetic retinopathy and diabetic macular edema (DR/DME).

Patients diagnosed with diabetic retinopathy may be particularly vulnerable to periods of low glucose, and keeping glucose levels stable should be an important part of glucose control.

Carolyn Majcher, OD, FAAO, provides an overview of the symptoms of diabetic retinopathy and diabetic macular edema (DR/DME) and recommendations for dilated eye exams for patients with type 1 and type 2 diabetes.

Carolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss the current prevalence and future projections of diabetic retinopathy and diabetic macular edema (DR/DME) as well as the impact of early diagnosis and treatment for patients with diabetic retinal diseases.

According to the company, it is planning an end-of-phase 2 meeting with the FDA to discuss the results.

According to researchers, factors that were associated with all type of visual impairment included older age, lower education level, and lower income were associated with all types of visual impairment.

The research team, led by Jayantha Gunaratne, PhD, senior principal investigator at IMCB, conducted a comprehensive analysis of the eye fluid samples from a well-defined cohort of proliferative DR patients against the control cohort to deduce impaired mechanistic aspects within the eye.

Investigators have found that cells within retinal blood vessels are endowed with a previously unappreciated ability to acquire resistance against the damaging effects of hyperglycemia in patients with diabetes mellitus.

Intravitreally injected anti-VEGF drugs are undergoing investigation as researchers look for new treatment options.

Delaying the disease can also delay any onset of vision problems, including diabetic retinopathy and diabetic macular edema.

Being able to visualize and evaluate the retinal periphery provides a better understanding of the disease status and supports a better treatment decision.

An end-of-week review of retina news and stories from October 29-November 3, 2022.

RGX-314 is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions.

Data highlights need for educational materials and training resources in DME and DR.

A combination of posters, podium presentations, and instructional courses provided invaluable revelations to the ophthalmic community.

The investigators emphasized that hydroxychloroquine doses of 5 mg/kg/day or less, in accordance with current ophthalmology and rheumatology guidelines, was associated with a higher risk of lupus flares, and the threshold was near 5 mg/kg/day.

Oral APX3330 was found to demonstrate favorable safety and tolerability profile in interim masked safety results, consistent with 11 prior trials of APX3330.

The Phase 2 Altitude study is an open-label, randomized, controlled, dose-escalation evaluation of RGX-314, evaluating the efficacy, safety, and tolerability of suprachoroidal delivery of RGX-314 in patients with moderately severe/severe non-proliferative diabetic retinopathy or mild proliferative diabetic retinopathy.

This year’s hybrid meeting will allow attendees to participate in person or virtually. Either way, this congress will offer a wealth of information to specialists covering all aspects of retinal diseases.

Nancy Lurker, CEO of EyePoint Pharmaceuticals, shares the 12-month safety data from the DAVIO trial, investigating EYP-1901 for the treatment of wet age-related macular degeneration (AMD) and nonproliferative diabetic retinopathy.

While the COVID-19 pandemic revealed the potential of utilizing artificial intelligence in screening for diabetic retinopathy, improvements are still needed as a results of the number of images that are ungradable.

A team of scientists, led by Andrzej Foik, PhD, of the International Center for Translational Eye Research, is working on new therapies that may slow vision loss in patients diagnosed with retinal degeneration.

Kerrie Brady, CEO of OcuTerra Therapeutics, shares an update on their eye drop-based integrin inhibitor, which is intended to be a novel therapy for diabetic retinopathy.

The ASRS "See for a Lifetime; See a Retina Specialist" initiative will spotlight early detection and outline the importance of seeing a retina specialist.